Bevacizumab in breast cancer: fundamental questions remain.
Mount Vernon Cancer Centre, Northwood, Middlesex HA6 2RN, UK. david.miles@doctors.org.uk
David W
DW
Miles
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use*
D061067:Antibodies, Monoclonal, Humanized; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D017239:Paclitaxel; D005472:Fluorouracil